Milestone Scientific Inc.

MLSS: S-3/A · shelf registration

Milestone Scientific filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration on September 18, 2026, solely to correct a clerical error: the original filing's signature page inadvertently omitted the company's signature block. The underlying shelf registration (File No. 333-298804), originally filed September 8, 2026, covers up to an aggregate offering price of $45,000,000 of common stock, preferred stock, warrants, rights, and units, to be sold from time to time on a delayed or continuous basis under Rule 415. The amendment also attaches a conformed Exhibit 5.1 legal opinion from Tarter Krinsky & Drogin LLP and does not modify the prospectus or any other Part II information. No securities have been priced or sold under the shelf; the meaningful dilution signal will come from any future prospectus supplement, not this housekeeping amendment.

SEC S-3/A•1mo ago

MLSS: S-3 · shelf registration

Milestone Scientific filed a Form S-3 universal shelf registration on September 8, 2026, registering up to $45,000,000 of securities — common stock, preferred stock, warrants, subscription rights, and units — for sale from time to time in one or more offerings. Most of the capacity is carry-forward: $41,763,620 of unsold securities from the company's prior shelf (File No. 333-275088, effective October 30, 2023), with only $3,236,380 newly registered. The $446.94 filing fee was fully offset by fees paid on the prior registration, so the net fee due is $0. Proceeds are earmarked for working capital and general corporate purposes, with management retaining broad discretion over allocation. Context is significant: the filing repeats going-concern language, notes MLSS closed at $0.46 per share on September 2, 2026, and flags the risk of failing to regain or maintain compliance with NYSE American listing requirements. No securities are being sold at this time. Any future takedown would dilute the 90,644,403 shares outstanding as of September 8, 2026, and the risk factors explicitly warn that actual or perceived sales under the shelf could materially dilute stockholders and pressure the stock price.

SEC S-3•1mo ago

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

Milestone Scientific announced it will host a conference call on August 14, 2026, to discuss its second quarter 2026 financial results and corporate progress. The company specializes in computerized drug delivery instruments for medical and dental applications, utilizing its proprietary DPS Dynamic Pressure Sensing Technology. Investors can access the live call starting at 8:30 AM Eastern Time via telephone or webcast, with a replay available until August 28.

•2mo ago

MLSS: 8-K · proxy statement

Milestone Scientific Inc. reported the results of its 2026 Annual Meeting held on July 27, 2026, where stockholders elected five incumbent directors and approved proposals to increase authorized shares and amend the equity incentive plan. All proposals passed, including the ratification of Grassi & Co. Certified Public Accountants, PC as the independent auditor for the fiscal year ending December 31, 2026. Subsequent to the mailing of the proxy materials, the Board elected Kelly Ulto and Greg Shilling as directors to fill vacancies and serve on key committees. The Board subsequently re-elected them to serve until the 2027 Annual Meeting, reaffirming their independence and appointing Ms. Ulto as Chair of the Audit Committee and Mr. Shilling as Chair of the Compensation Committee.

SEC 8-K•2mo ago

MLSS: 8-K · other

Milestone Scientific Inc. disclosed that three directors have submitted notices to convert their remaining principal holdings in the company's Convertible Bridge Notes into common stock. The notices were received from Benedetta Casamento, Dr. Didier Demesmin, and Neal Goldman, covering a combined principal balance of approximately $466,000 plus accrued interest. The conversions will take effect automatically once the fair value of the common stock reaches at least $0.50 per share and the directors comply with insider trading policies. No shares have been issued yet, and the original notes were issued for an aggregate principal amount of $800,000 prior to a partial conversion in April 2026.

SEC 8-K•2mo ago

MLSS: DEF 14A · proxy statement

Milestone Scientific filed its definitive proxy statement for the 2026 annual meeting, requesting stockholder approval for five proposals. Key proposals include the election of five directors, an increase in authorized common stock from 125 million to 135 million shares, and an increase in the share reserve of the 2020 Equity Incentive Plan from 11.5 million to 28.75 million shares. The expansion of the equity plan is intended to cover the settlement of 11.2 million performance-based restricted stock units (PRSUs) recently granted to senior executives, including CEO Eric Hines. The company noted that the new shares represent an 11.31% basic dilution and are necessary to support retention and performance incentives without increasing cash compensation. The proxy also discloses a repricing of underwater stock options for the CEO and Senior VP of Sales in April 2026, reducing the exercise price to $0.31 per share. Additionally, the company seeks ratification for a new independent auditor, Grassi & Co., following the departure of CBIZ CPAs, and details significant related party transactions with supplier United Systems.

SEC DEF 14A•4mo ago

Milestone Scientific Reports Financial Results for First Quarter 2026

Milestone Scientific reported Q1 2026 revenue of $2.16 million, a 3% decrease from the prior year, but maintained a relatively stable revenue base despite shipping challenges to the Middle East. The company significantly reduced its operating loss to $828,000, an improvement of $1.2 million from the $2.0 million loss in Q1 2025, driven by a 30% reduction in operating expenses. Management reaffirmed its outlook for 2026, expecting double-digit revenue growth of $9.8 million to $10.2 million, driven by expanding commercial adoption in both dental and medical segments. However, the company's 2025 financial statements included an audit report emphasizing substantial doubt about its ability to continue as a going concern, which remains a significant risk despite recent cost reductions and a $2.15 million capital raise in April 2026.

•5mo ago

MLSS: 10-Q · periodic report

Milestone Scientific Inc. reported a net loss of $839,853 for the three months ended March 31, 2026, compared to a net loss of $1,994,586 for the same period in 2025, representing a significant improvement in operating performance. The company's total product sales for the three months ended March 31, 2026 were approximately $2.2 million, a decrease of $70,387 or 3% from the prior year. This decline was primarily due to lower international distributor demand, influenced by ongoing geopolitical tensions. Revenue from China was not recognized during the current period, compared to $110,000 in the prior period. The company has received a purchase order in April 2026, indicating renewed activity in that market. Medical revenue increased to approximately $108,000, up 110% from the prior period, reflecting continued early-stage adoption of the company’s medical products.

SEC 10-Q•5mo ago

Milestone Scientific Schedules First Quarter 2026 Financial Results and Business Update Conference Call

Milestone Scientific announced it will host a conference call on May 14, 2026, at 8:30 AM ET to discuss first quarter 2026 financial results and corporate progress. The event will be accessible via live webcast and telephone, with an audio replay available through May 28, 2026. The company develops computerized drug delivery instruments and injection technologies for medical and dental applications.

•5mo ago

Milestone Scientific Inc. Completes $2.15 Million Private Placement

Milestone Scientific closed a $2.15 million private placement consisting of common stock and warrants at $0.27 per unit. The deal included approximately $1.8 million in cash proceeds and the conversion of $351,000 in bridge notes, with insiders participating on the same terms. Gross proceeds could reach $2.69 million if warrants are fully exercised, and the company plans to use the funds to scale sales, inventory, and marketing.

•6mo ago